GlassScriptPhysician profile
Sarah D Bourland
NPI 1801987342
$4,515.14
in general payments reported to CMS, 2019-2025
29 companies · $654 in 2025
The $654 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $313 · 2021: $517 · 2022: $760 · 2023: $670 · 2024: $761 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,369.56 | 2020-2025 | Bexsero, Fluarix Quadrivalent, Penmenvy |
| Sanofi Pasteur INC. | $505.74 | 2019-2025 | |
| Tris Pharma INC | $365.97 | 2019-2022 | |
| Corium, LLC | $320.04 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $201.08 | 2019-2024 | |
| Pfizer INC. | $159.90 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $156.06 | 2019-2025 | Gardasil 9, Vaxelis, Rotateq |
| Biogen, INC. | $122.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $120.44 | 2019 | |
| Cranial Technologies, INC | $119.91 | 2021-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $118.83 | 2023-2024 | Qelbree, Qelbree |
| Palette Life Sciences, INC. | $118.75 | 2020 | |
| Alexion Pharmaceuticals, INC. | $116.85 | 2019 | |
| Genzyme Corporation | $110.90 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.90 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $78.11 | 2023-2025 | Grastek, Odactra, Ragwitek |
| Shire North American Group INC | $77.22 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $63.89 | 2022 | |
| Genentech USA, INC. | $53.16 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $40.45 | 2025 | Relexxii |
| Kaleo, INC. | $39.07 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $24.53 | 2025 | Neffy |
| Photocure INC | $23.88 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.19 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.34 | 2025 | Alvesco |
| Collegium Pharmaceutical, INC. | $18.49 | 2025 | Jornay Pm |
| Karl Storz Endoscopy-America | $17.27 | 2019 | |
| Seqirus USA INC | $16.05 | 2023 | Flucelvax Quadrivalent |
| Verrica Pharmaceuticals INC. | $15.48 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bourland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.